/
Description of Our Business We are a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
The business is unprofitable at the operating level (-40274.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
ROIC dropped from -82.39% to -130.58%, capital efficiency is deteriorating. Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$90K
Net Income (TTM)
-$23M
▲ +11.4% YoY
Op. Margin
-40274.44%
ROIC
-165.95%
▼ -48.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$23M
▲ +25.4% YoY
Op. Cash Flow (TTM)
-$23M
▲ +25.7% YoY
Net Debt
-$41M
Net Cash Position
Cash & Equiv.
$42M
3Y CAGR: -57.2%
Continue Research